采用培养胎肝细胞分泌上清治疗５０例慢性重型肝炎（慢重肝），２周后血清总胆红素、转氨酶下降和凝血酶原活动度、白蛋白及甲胎蛋白升高例数大于对照组（Ｐ＜０．０５，Ｐ＜０．０１）。３～４周后，治疗组总有效率（即存活率）达７２％，与对照组３８％（１９／５０）的存活率相比，差异显著（Ｐ＜０．０１）。结果表明，胎肝细胞分泌上清治疗慢重肝疗效明显，无副作用，可替代已中止的胎肝细胞输注疗法。 Fifty patients with chronic severe hepatitis (chronic severe hepatitis) were treated with cultured fetal hepatocyte supernatant, and serum total bilirubin, aminotransferase and prothrombin activity were decreased after two weeks. The cases of elevated albumin and alpha-fetoprotein were higher than those of control Group (P <0.05, P <0.01). After 3 to 4 weeks, the total effective rate (ie, survival rate) in the treatment group was 72%, which was significantly different from that in the control group (19/50) (P <0.01). The results show that the fetal liver cells supernatant for the treatment of chronic severe hepatitis with obvious side effects, can replace the termination of fetal liver cell infusion therapy.